

WHERE AI BECOMES REALITY




Disclaimer

This document contains certain forward-looking statements with respect to the Corporation. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. We consider the assumptions on which these forward-looking statements are based to be reasonable, but caution the reader that these assumptions regarding future events, many of which are beyond our control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect us. These risks and uncertainties include risks associated with market acceptance, competitive developments and other factors. Except for ongoing obligations under securities laws to disclose all material information to investors, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

www.diagnos.ca

© 2019 | Diagnos inc. All Right Reserved





All eyes have a story

We help you read it through

Artificial intelligence

DIAGNOS is a leader in artificial intelligence and healthcare technical services including algorithm development, data analysis, and image processing since 2001.

Our mission is early detection of critical health issues through the use of AI.

www.diagnos.ca

© 2019 | Diagnos inc. All Right Reserved

DIAGNOS
Your Knowledge Partner

ABOUT DIAGNOS

OUR MISSION IS EARLY DETECTION OF CRITICAL HEALTH ISSUES THROUGH THE USE OF AI.

- A Canadian fast growing, AI driven Healthcare Diagnostic company with FDA, Health Canada, CE and other multi-country regulatory approvals. It operates at different degrees of deployment, in 14 countries with installations in hospitals, clinics and mobile vans.
- Our current main market is screening diabetic patients for retinopathy. Digital fundus imaging resolution which has been pioneered by Diagnos allows for diagnosis of diabetic and hypertensive retinopathy empowering the first level of attention/primary care facilities, accurate on-real time referral to retina specialist to save patient's vision (est. only 1800 retinal specialists in U.S.) leading to an unserved segment in the market and particularly in emerging markets where specialists are almost non-existent.
- Asymptomatic patients often have sudden or partial loss of vision which can be prevented by Diagnos' technology which requires no prep work on the eye and quick analysis done by Artificial Intelligence. Using FDA approved telemedicine, Diagnos can save money and lives by having triage and referral pathway automated.
- Diabetes inflicts massive costs to Governments and other Health Care Providers or Sponsors including Insurance Companies. Diagnos can reduce these costs drastically by insuring that all diabetics are screened annually.
- Diagnos is also working on several additional indications using the same retina images. A Hypertension, Stroke and Cardiovascular detection application is in final stages of development and others will follow.
- Collaborative pharma companies benefit from early alternative diagnosis of diabetic condition.

What you should know about our advantages:

1. The algorithms we have developed are the foundation of the company.
2. The medical structures today demonstrates the need for our solution.
3. Multi national companies such as IBM, Google and others are also analyzing retina images.
4. We are better today because we started before them and we worked in the field not in labs.
5. We have a database of screened individuals of over 400,000 diabetics and hypertensive patients today to optimize our algorithms. These patients come from 16 countries.
6. The lack of specialists is making this solution mandatory for the future.
7. A fast (2 minutes) diagnostics of the retina is what is required, and we do that.
8. Our science as been developed over the last 15 years and it works.
9. Our goal is to save money to government and taking care of the patients at the same time.

Regulatory Compliance

ISO 13485 : 2016

CERTIFIED

HEALTH CANADA

LICENSED

USA-FDA

CLEARED

HIPAA

COMPLIANT

CE MARK


COMPLIANT

Cofepris-Mexico

CLEARED

Saudi-FDA

Pending



Market Statistics

Trading Symbol :ADK.v Canada, DGNOF USA	
Share Price (As at 015-03-19)	\$0.35
Number of Shares Outstanding	39,000,000
Number of Stock Options	1,612,268
Debt	\$150,000
Number of Warrants	942,000
Fully diluted number of Shares	45,713,949
Market Cap.	\$18M
Insider Ownership (%)	8%

www.diagnos.ca

© 2019 | Diagnos inc. All Right Reserved

Board of Directors

André Larente, CEO, Diagnos

Mr. Larente has previously held leading management positions with companies such as Siemens, Newbridge Networks, Cognos, Tandem Computers and Honeywell Information Systems.

Georges Hébert

Mr. Hébert brings a wealth of experience in governance of public and private companies. He was a director at the Laurentian Bank, where he served for twenty years as a member of the Audit committee.

Dr. Jean-Francois Yale

Dr. Yale is an endocrinologist, currently Professor of Medicine in the McGill University Department of Medicine. Dr. Yale chaired the Clinical and Scientific Section of the Canadian Diabetes Association ("CDA") from 1992-1994. Dr. Yale's research interests (210 publications).

Dr Reid MacLellan

Dr. Maclellan is currently an Instructor of Surgery at Harvard Medical School and Boston Children's Hospital. Dr. Maclellan currently serves on the board of directors for five organizations, including both for-profit and not-for-profit.

Francois Côté

TELUS Ventures chairman François Côté oversees investment strategy development and implementation and value creation for TELUS. François has held a number of management positions over his almost 30 years' career. In 2004, he was appointed president and CEO of Emergis. Following TELUS' acquisition of Emergis in January 2008, he was appointed president of TELUS Québec, TELUS Health, and TELUS Ventures. He has served on the boards of the Montreal Heart Institute, Lumenpulse Inc., and EXFO since January 2015. In June 2013, he was named Honorary Lieutenant-Colonel of the Canadian Force's 34th Signal Regiment.

Advisory board: Dr Neil Bressler, Chief - Retina Division,, Johns Hopkins Medicine, Dr Jason S. Slakter, M.D. is a board certified retinal and macular disease specialist, Clinical Professor of Ophthalmology at New York University School of Medicine.

www.diagnos.ca

© 2019 | Diagnos inc. All Right Reserved

DIAGNOS
Your Knowledge Partner

MARKET OPPORTUNITY 1



Market **key insights**

- **Diabetic Retinopathy Market Size was valued at USD 8 billion in 2018 and is expected to witness 6.9% CAGR from 2019 to 2025.**
- **Favourable reimbursement policies available for ophthalmologic surgeries should positively influence diabetic retinopathy market growth.**
- **North America diabetic retinopathy market was valued at USD 3 billion in 2018 and will witness robust growth over the forecast period.**
- **Some of the major industry players operative in the diabetic retinopathy market include Google, IBM, Novartis, Regeneron Pharmaceuticals, Genentech, Allergan and Bayer AG, Aerpio Pharmaceuticals, Ampio Pharmaceuticals, BCN Peptides, ThromboGenics, Kowa Company, and Alimera Sciences.**

(Research Cosmos, A Global Library of Market Research Reports)

www.diagnos.ca

© 2019 | Diagnos inc. All Right Reserved


DIABETES

Worldwide

The global cost of diabetes is now \$825 billion dollar according to the largest ever study of diabetes levels across the world. (The Lancet Diabetes & Endocrinology Study)

Number of people with diabetes has risen from 108 million in 1980, to 422 million in 2014. (WHO)


Assuming we screen 253M patients @ \$15= \$3.8B is the market size.




Source: WHO 2016

CARDIOVASCULAR

Worldwide



The Global Burden of Cardiovascular Disease, American College of Cardiology 2017



Source: WHO

SALES AND MARKETING 2

OVERVIEW





Artificial intelligence market

- AI in healthcare aims to improve patient outcomes by assisting healthcare practitioners in using medical knowledge.
- The AI market for healthcare applications is expected to achieve rapid adoption globally, with a compound annual growth rate (CAGR) of **42 percent until 2021**.
- By 2020, chronic conditions such as cancer and diabetes are expected to be diagnosed in minutes using cognitive systems.
- By 2025, AI systems are expected to be implemented in **90 percent of the US and 60 percent of the global hospitals and insurance companies**.

www.diagnos.ca

© 2019 | Diagnos inc. All Right Reserved

DIAGNOS
Your Knowledge Partner

Product Pipeline

Analysis of multiple pathology with same hardware (camera)

1. Retinal CARA (2019) in production
 - Filing for US FDA on algorithms, July 2019
 - Saudi FDA, May 2019
2. CARA-HT, HYPERTENSION (October 2019)
3. CARA-S; STROKE (2021)
4. CARA-C; CARDIO (2021)

More than one application using the medical imaging of the retina.

www.diagnos.ca




Value proposition

- **Patient** : Convenient non-invasive test & trip to specialist only if necessary.
- **Diabetologist/GP/Endo** : Higher patient compliance & additional pertinent patient information
- **Retina Specialist** : Increased focus on treatable cases & increased revenue.
- **Pharmaceutical Company** : Increased drug sales volume
- **Insurance Company** : Increased patient compliance & decreased health plan expenditure
- **Government** : Significant cost avoidance mid/long term & positive political optics

SOLUTION OVERVIEW

3

Telemedicine / Referral Pathway



- Tele-ophthalmology platform
- Integrates with almost any camera
- Comprises of image upload, automated, pre-screening, grading and referral interface
- Modules extend functionality
 - Enhancement
 - Automated pre-Analysis (DR)
 - Automated pre-Analysis (other)

www.diagnos.ca



© 2019 | Diagnos inc. All Right Reserved

Automatic Detection and Triage (Diabetic Retinopathy)

Our algorithms are capable of :

- Automatic detection of pathology in retinal photographs
- Lesion classification
- Pre-triaging patients in order of severity

*Automated triage can help reduce
healthcare labour requirements while
increasing patient access to quality care
and reducing healthcare expenditure*



www.diagnos.ca

© 2019 | Diagnos inc. All Right Reserved


DIAGNOS
Your Knowledge Partner

Automatic Detection and Triage (Cardio vascular and Hypertension)

Our algorithms are capable of :

- Automatic detection of pathology in retinal photographs
- Lesion classification
- Pre-triaging patients in order of severity

Automated triage can help reduce healthcare labour requirements while increasing patient access to quality care and reducing healthcare expenditure



www.diagnos.ca

© 2019 | Diagnos inc. All Right Reserved

DIAGNOS
Your Knowledge Partner

Deployment Revenue Options

We are flexible with regards to our screening options

- Mobile (\$\$\$\$)



- Managed (\$\$\$)



- Standalone (\$\$)



- Software only (\$)



www.diagnos.ca


© 2019 | Diagnos inc. All Right Reserved

DIAGNOS
Your Knowledge Partner

FINANCIAL OVERVIEW 4

Revenue Growth Plan

Management will focus on three core pillars of revenue growth to drive shareholder value:



www.diagnos.ca

© 2019 | Diagnos inc. All Right Reserved

DIAGNOS
Your Knowledge Partner

Strategy and proof

concept March 2018

Pharma

Offer turn key wellness programs to increase their revenues -

DONE

Primary care facility

Taking care of diabetic patients and hitting HEDIS scores for US -

DONE

Governments

Reduce cost initiatives through prevention program -

Done



Government prospects

- **Quebec Government (in pilot at CHUM)**
- **Colombia (through our local partner)**
- **Saudi Arabia (through our local partner)**
- **Bangladesh (through our local partner)**
- **Mexico (ISSSTE , IMSS and ISSEMyN (proposal state))**
- **Panama (through our local partner)**

A black and white close-up photograph of a person's eye, looking slightly to the right. The eye is dark and has long, dark eyelashes. The skin around the eye is visible, showing some texture and shadows.

Customers

Pharma

- **Novartis UAE, Novartis Sudan, Poland, Mexico, Nigeria. New countries for 2019 includes Canada, Europe, Malaysia and others**
- **Novo Nordisk (starting in Mexico)**
- **Sanofi (proposal state in Algeria)**
- **Merck Frost Canada (proposal state)**
- **Pfizer Brazil (proposal state)**

A black and white close-up photograph of a person's eye, looking slightly to the right. The eye is detailed, showing eyelashes and the iris. A green rectangular box is overlaid on the top left of the image, containing the word "Customers" in white text.

Customers

Primary care

- Chapparal Group (California- 2 years)
- 20-20 Now (started in November 2018)
- Optina (Starting in December (2018))

Consolidated Revenue Potential

DIAGNOS Inc.						
Financial Highlights						
	Year ending March 31,					
	2021		2022		2023	
	Forecast					
	(\$'000)					
	Worst Case	Best Case	Worst Case	Best Case	Worst Case	Best Case
Revenue	\$3,700	\$9,000	\$12,500	\$18,000	\$27,000	\$37,000
COGS	(500)	(1,400)	(3,100)	(4,500)	(6,800)	(9,300)
Operating Expenses	(2,850)	(3,400)	(3,700)	(3,700)	(4,100)	(4,100)
EBITDA	\$350	\$4,200	\$5,700	\$9,800	\$16,100	\$23,600
Depreciation	(250)	(250)	(300)	(300)	(300)	(300)
Interest expense	-	-	-	-	-	-
Income taxes	-	-	-	-	(2,415)	(3,540)
Net profit	\$100	\$3,950	\$5,400	\$9,500	\$13,385	\$19,760

www.diagnos.ca

© 2019 | Diagnos inc. All Right Reserved



André Larente

President, CEO, DIAGNOS inc.

alarente@diagnos.com

+ 1 (450) 678-8882, Ext. 224

Corporation's office

Suite 340, 7005 Taschereau Blvd.
Brossard, Quebec, J4Z 1A7, Canada
info@diagnos.com

TSXV : ADK.V

OTCQB : DGNOD



Hadi Chakor
Chief Medical Officer



Marc-André Massue
VP - Finances



Guillermo Moreno Robles
VP - Sales



Yves-Stéphane Couture
VP - Sales